NDUFC2

Across TCGA pan-cancer cohorts, NDUFC2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NDUFC2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where NDUFC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NDUFC2 is over-expressed in tumor, although a few such as KIRP and KIRC show the opposite, repressed pattern.

BLCA, KIRP, and KIRC are the cancer types where NDUFC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NDUFC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.662	<.001	11	view →
KIRP	Male	All	−0.720	<.001	9	view →
KIRC	Male	All	−0.463	<.001	8	view →
STAD	Female	All	+1.028	<.001	6	view →
BRCA	All	III,IV	+0.648	<.001	6	view →
LIHC	Male	All	+0.636	<.001	6	view →
THCA	Male	III,IV	−0.517	.022	3	view →
KICH	All	All	−0.449	.004	3	view →
LUAD	All	All	+0.177	.010	3	view →
ESCA	All	All	+0.724	.023	2	view →
CHOL	All	II,III,IV	−0.269	.017	2	view →
PRAD	All	All	−0.180	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NDUFC2–BLCA

Open the BLCA breakdown →